Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...

Antihypertensive Drugs: Types of β-Blockers

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Absence of coronary artery disease in patients undergoing coronary imaging and association with amyloidosis: A Danish nationwide study.

American heart journal·2025

Same author

First-in-Human Experience With a Biventricular, Pulsatile MCS Platform Technology Avoiding Blood Contact: Translational Insights.

JACC. Basic to translational science·2025

Same author

Influence of Obesity on Invasive Hemodynamics and Prognosis in Patients With Heart Failure.

JACC. Heart failure·2025

Same author

Ventricular arrhythmias in acute heart failure. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), the European Heart Rhythm Association (EHRA) and the Heart Failure Association (HFA) of the ESC.

European journal of heart failure·2025

Same author

Understanding Platelet Activation in the Aeson Bioprosthetic Total Artificial Heart: Insights From Aspirin Treatment and Outcomes.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2025

Same author

Adenovirus Infections and Disease in Solid Organ Transplant Recipients: Incidence and Outcomes.

Open forum infectious diseases·2025

Search research articles

Related Experiment Videos

Bisoprolol for congestive heart failure.

Jens Rosenberg¹, Finn Gustafsson

¹Research Fellow Frederiksberg University Hospital, Cardiology Department, Nordre Fasanvej 57-59, 2000 Frederiksberg, Denmark. cor@dadlnet.dk

Expert Opinion on Pharmacotherapy

|January 19, 2008

Summary

Bisoprolol is an effective beta-blocker for systolic heart failure. This highly selective beta(1)-antagonist is well-tolerated and recommended as a first-line treatment for heart failure patients.

Area of Science:

Cardiology
Pharmacology

Background:

Beta-blockers are essential for treating systolic heart failure.
Not all beta-blockers are equally effective in this condition.

Purpose of the Study:

To determine the role of bisoprolol, a selective beta(1)-antagonist, in managing congestive heart failure stemming from systolic dysfunction.

Main Methods:

Searched PubMed and BIOSIS databases for 'bisoprolol' and 'heart failure'.
Reviewed randomized clinical trials and pharmacological data.
Gathered supplementary information from reference lists and the FDA website.

Main Results:

Bisoprolol demonstrated efficacy in patients with moderate-to-severe systolic heart failure.
The CIBIS trials provided key data on bisoprolol's effectiveness.

Related Experiment Videos

Conclusions:

Bisoprolol is a well-tolerated, effective first-line beta-blocker for systolic heart failure.
Evidence primarily supports its use in moderate-to-severe cases based on CIBIS trials.